Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LQ085
- Development stage
- Preclinical
- Lead developer
- Novamab Biopharmaceuticals
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
LQ085 is a preclinical-stage bispecific VHH nanobody being developed by Novamab for the treatment of autoimmune diseases. Utilizing Novamab's proprietary nanobody platform, LQ085 is designed for subcutaneous administration. While the specific molecular targets remain undisclosed, the drug is engineered as a bispecific agent, likely targeting two distinct epitopes or pathways involved in the pathogenesis of autoimmune conditions. As a VHH-based biologic, it offers potential advantages such as high stability, high affinity, and the ability to reach epitopes inaccessible to conventional antibodies.
Beyond the preview
Go deeper on LQ085.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LQ085.